![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Departments of Medicine and Nutritional Sciences, University of Toronto, Toronto, Ontario, Canada; Division of Gastroenterology, St. Michael’s Hospital, Toronto, Ontario, Canada
3To whom correspondence should be addressed. E-mail: youngin.kim{at}utoronto.ca.
ABSTRACT
The inheritance of information based on gene expression levels is known as epigenetics, as opposed to genetics, which refers to information transmitted on the basis of gene sequence. In contrast to genetic changes observed in cancer, epigenetic changes are gradual in onset and are progressive, their effects are dose-dependent and are potentially reversible. These observations present new opportunities in cancer-risk modification and prevention using dietary and lifestyle factors and potential chemopreventive drugs. In this regard, folate, a water-soluble B vitamin, has been a focus of intense interest because of an inverse association between folate status and the risk of several malignancies (in particular, colorectal cancer) and of its potential ability to modulate DNA methylation. DNA methylation is an important epigenetic determinant in gene expression, in the maintenance of DNA integrity and stability, in chromosomal modifications, and in the development of mutations. Aberrant patterns and dysregulation of DNA methylation are mechanistically related to colorectal carcinogenesis. Folate plays an essential role in one-carbon transfer involving remethylation of homocysteine to methionine, thereby ensuring the provision of S-adenosylmethionine, the primary methyl group donor for most biological methylation reactions. The portfolio of evidence from animal, human, and in vitro studies suggests that the effects of folate deficiency and supplementation on DNA methylation are gene and site specific, and appear to depend on cell type, target organ, stage of transformation, and the degree and duration of folate depletion.
KEY WORDS: • folate • colorectal cancer • epigenetics • DNA methylation
Epigenetics
The inheritance of information based on gene expression levels is known as epigenetics, as opposed to genetics, which refers to information transmitted on the basis of gene sequence (1). The field of epigenetics therefore is the study of modifications of DNA and DNA-binding proteins and histones that alter the structure of chromatin without altering the nucleotide sequence of DNA; some of these modifications may be associated with heritable changes in gene function (2). Silencing is a subset of epigenetics, whereby gene expression and function are permanently lost. Although the involvement of RNA interference in epigenetic silencing has been clearly shown in yeasts and plants, it is not well understood in mammalian cells yet. Thus, in mammals, 2 systems, including DNA methylation and histone modifications (acetylation, methylation, ubiquitylation, and phosphorylation), are used to initiate and sustain epigenetic silencing (2).
DNA methylation
DNA methylation is an important epigenetic determinant in gene expression (an inverse relation), in the maintenance of DNA integrity and stability, in chromatin modifications, and in the development of mutations (3). The pattern of methylation at cytosine residues in the cytosine-guanine (CpG)4 sequences is a heritable, tissue- and species-specific, postsynthetic modification of mammalian DNA (3). Three to 4% of all cytosines in the human genome are methylated, and the resulting 5-methylcytosines make up 0.75–1% of all nucleotide bases in normal human DNA (1). CpG sites are unevenly distributed in the mammalian genome; vast stretches of sequence (
99% of the genome) are deficient for CpGs, and these are interspersed by CpG clusters called CpG islands (Fig. 1) (1). Seventy to 80% of all CpG sites in human DNA are normally methylated (1). However, this methylation occurs primarily in the bulk of the genome where CpG density is low, including exons, noncoding regions, and repeat DNA sites, and allows correct organization of chromatin in active and inactive states (4). Methylation of the CpG-depleted bulk of the genome facilitates transcriptional silencing of noncoding regions, which prevents the transcription of repeat DNA elements and parasitic DNA sequences (endogenous retroviruses and transposons that account for >35% of the human genome) (4). Parasitic DNA elements represent a significant threat to the structural integrity of the genome by promoting chromosome rearrangements or translocation or by directly disrupting genes or causing transcriptional interference (5).
|
DNA methylation is a dynamic process between active methylation, mediated by CpG methyltransferases (DNMT1, 3a, 3b) using S-adenosylmethionine (SAM) as the methyl donor, and removal of methyl groups from 5-methylcytosine residues by both passive and active mechanisms including demethylation by a purported demethylase (MBD2) (7).
DNA methylation and cancer
In contrast to methylated CpG sites in the CpG-poor bulk of the genome and unmethylated CpG islands in normal cells, cancer cells simultaneously harbor widespread loss of methylation in the CpG-depleted regions where most CpG dinucleotides should be methylated and gains in methylation of CpG islands in gene promoter regions (Fig. 1) (3,4).
Global hypomethylation is an early, and consistent, event in carcinogenesis (3,4). Global hypomethylation of the coding and the noncoding regions and demethylation of repetitive DNA sequences contribute to the development of cancer through the following mechanisms: chromosomal instability, increased mutations, reactivation of intragenomic parasitic sequences that could be transcribed and moved to other sites where they could disrupt normal cellular genes, mitotic recombination leading to loss of heterozygosity and promotion of rearrangements, aneuploidy, loss of imprinting, and upregulation of protooncogenes (1). However, animal studies have shown that genomic demethylation may protect against some cancers (e.g., intestinal tumors) (8,9) but may promote chromosomal instability and increase the risk of cancer in other tissues (e.g., lymphoma, sarcoma) (10,11).
Methylation at promoter CpG islands is an important mechanism of silencing transcription in carcinogenesis; the affected genes are silenced, and their function is stably lost in a clonally propagated fashion (1,4,12–14). Many genes inactivated by promoter CpG methylation in carcinogenesis have classic tumor-suppressor function or play critical roles in cell-cycle control, repair of DNA damage, apoptosis, differentiation, angiogenesis, metastasis, growth-factor response, drug resistance, and detoxification (4). Promoter CpG islands of over 60% of tumor suppressor and mismatch repair genes have been observed to be methylated in cancer (4).
Another means by which CpG methylation may contribute to carcinogenesis is the hypermutability of methylated cytosine. CpG dinucleotides within certain genes are not only the sites of DNA methylation but also mutational hot spots for human cancers (13). The majority of mutations observed in CpG sites are cytosine-to-thymine transitions mediated by the spontaneous deamination of 5-methylcytosine to thymine, by the enzymatic deamination of 5-methylcytosine to thymine by DNMT, and by the enzymatic deamination of unmethylated cytosine to uracil and subsequent methylation of uracil to thymine by DNMT (13). CpG sites have been shown to act as hot spots for germline mutations, contributing to 30% of all point mutations in the germ line, and for acquired somatic mutations that lead to cancer (5). For example, methylated CpG sites in the p53 tumor suppressor coding region contribute to as many as 50% of all inactivating mutations in colorectal cancer and to 25% of cancers in general (5).
Increased DNMT1, 3a, and 3b, and decreased MBD2 expression and activity have been observed in many human cancers (7). DNMT1 may promote tumorigenesis by its link to activation of the oncogenic ras signaling pathway, by increasing cellular proliferation by binding to proliferating cell nuclear antigen and by reducing cellular p21, a member of the cyclin-dependent kinase (CDK) inhibitor family that inhibits a wide range of cyclin-CDK complexes involved in G1 and S phase progression, by inhibition of p53-dependent apoptosis, and by promoter CpG island methyation of tumor suppressor and mismatch repair genes (7).
Folate and colorectal cancer risk
Epidemiologic studies over the past decade have suggested an inverse association of folate status (assessed by dietary folate intake or by the measurement of blood folate levels) with the risk of cancer of lungs, oropharynx, esophagus, stomach, colorectum, pancreas, cervix, ovary, prostate, and breast, and the risk of neuroblastoma and leukemia (15,16). Although the results from epidemiologic and clinical studies are not uniformly consistent, the portfolio of evidence indicates 20–40% reduction in the risk of colorectal cancer in subjects with the highest dietary intake or blood levels of folate compared with those with the lowest intake or blood levels (16–18). Several small intervention studies have demonstrated that folate supplementation can improve or reverse surrogate endpoint biomarkers of colorectal cancer (16,17), and some epidemiologic studies have shown a beneficial effect of multivitamin supplements containing 
400 µg folic acid on colorectal cancer risk and mortality (19–21). The data from animal studies generally support a causal relation between folate depletion and colorectal cancer risk and an inhibitory effect of modest levels of folate supplementation on colorectal carcinogenesis (17). However, animals studies have also shown that folate supplementation may increase colorectal cancer risk and accelerate colorectal cancer progression if too much is given or if it is provided after neoplastic foci are established in the colorectum (17,22).
Folate and DNA methylation
Folate, in the form of 5-methyltetrahydrofolate, is involved in remethylation of homocysteine to methionine, which is a precursor of SAM, the primary methyl group donor for most biological methylation reactions, including that of DNA (Fig. 2) (23). After transfer of the methyl group, SAM is converted to S-adenosylhomocysteine (SAH), a potent inhibitor of most SAM-dependent methyltransferases (Fig. 2) (23). Cravo and Mason (24) first proposed that a mechanism by which folate deficiency enhances colorectal carcinogenesis might be through an induction of genomic DNA hypomethylation based on the biochemical function of folate in mediating one-carbon transfer and on evidence from animal experiments that demonstrated methyl group donor deficiency induced DNA hypomethylation.
|
Diets deficient in methyl group donors (choline, folate, methionine, and vitamin B-12) are associated with spontaneous and chemically induced development of hepatocellular carcinoma in rats (15,16). Diets deficient in different combinations of methyl group donors have been consistently observed to induce genomic and protooncogene (c-myc, c-fos, c-Ha-ras) DNA hypomethylation and elevated steady-state levels of corresponding mRNAs and site-specific p53 hypomethylation in rat liver (15,16). Methyl group donor deficiency has also been shown to upregulate DNMT in rat liver (15,16). However, a recent study reported that a diet deficient in choline, methionine, and folate, which caused a 30% increase in DNA strand breaks, did not induce a significant degree of genomic DNA hypomethylation in rat colon, suggesting that the colorectum may be resistant to the hypomethylating effect of methyl group deficiency (25).
Recent animal studies using viable yellow agouti (Avy) mice have unequivocally demonstrated that maternal dietary methyl group supplementation with a modest amount of folic acid, vitamin B-12, choline, and betaine permanently alters the phenotype of the offspring via increased methylation at the promoter CpG site of the agouti gene (26–28). Furthermore, Waterland and Jirtle (28) have shown that the methylation status of the promoter CpG region of the agouti gene was highly correlated with the methylation status of the adjacent transposon gene. This indicates that there is a localized epigenetic instability in methylation that arises from an interaction between the transposon and its nearby genetic region, and that genes that manifest a transposon region adjacent to a promoter region of DNA could be influenced by in utero exposure to a methyl supplemented diet.
Effect of isolated folate deficiency on genomic DNA methylation in rodent liver and colon
Although isolated folate deficiency has been shown to reduce SAM levels and SAM to SAH ratios and increase SAH concentrations in rat liver (29–33), conflicting data exist for the effect of isolated folate deficiency on DNA methylation in rodent liver (Table 1). Severe folate deficiency of a short duration (4–6 wk) has been shown to either decrease (34) or increase (33) the extent of genomic DNA methylation in rat liver. A prolonged (15–24 wk), moderate degree of dietary folate deficiency failed to induce significant genomic DNA hypomethylation in rat liver (32). Recently, the same moderate folate deficient diet was shown to induce a significant 56% increase in genomic DNA methylation in the liver of mice after 5 wk; however, genomic DNA methylation returned to baseline values after 8 wk (35). Taken together, the results from these studies suggest that folate deficiency of a moderate degree or short duration appears to induce genomic DNA hypermethylation in rodent liver, likely due to compensatory upregulation of DNMT, and that the effect of sustained or severe folate deficiency on genomic DNA methylation in rodent liver is not consistent.
|
The effect of isolated folate deficiency on DNA methylation in the colorectum, a tissue that is particularly susceptible to increased carcinogenesis with folate deficiency, has not yet been clearly elucidated (Table 1). A moderate degree of folate deficiency alone or in conjunction with a colorectal carcinogen (dimethylhydrazine [DMH] or azoxymethane [AOM]) for 10–26 wk failed to induce significant genomic and gene-specific DNA hypomethylation in rat colon (25,32,36–39). In contrast, significant p53 hypomethylation in exon 8 but not in exons 6–7 was observed in the DMH-treated rat colon in conjunction with folate deficiency. It remains unclear whether this was due to the DMH, the folate deficiency, or the combination of the two. This was effectively overcome in a dose-dependent manner by increasing levels of dietary folate (40). A recent study showed that, despite a marked reduction in plasma and colonic folate concentrations, a large increase in plasma homocysteine concentrations, and a progressive decrease in colonic SAM to SAH ratios, isolated folate deficiency did not induce significant genomic DNA hypomethylation in the colon (41). Paradoxically, isolated folate deficiency significantly increased (by 30%) the extent of genomic DNA methylation in the colon at an intermediate time point (41), which is consistent with prior observations made in rodent liver (33,35). Folate supplementation did not modulate colonic SAM, SAH, SAM to SAH ratios, or genomic DNA methylation at any time point (41). The extent of p53 methylation in the promoter and exons 6–7 was variable over time at each of the CpG sites examined, and no associations with time or dietary folate were observed at any CpG site (41). Steady-state levels of p53 mRNA did not significantly correlate with either genomic or p53 methylation within the promoter region and exons 6–7 (41). These observations suggest that isolated folate deficiency does not induce consistent and predictable changes in p53 methylation in rat colon, whereas it may produce p53 hypomethylation in specific exons in rat liver and in rat colon in conjunction with alkylating agents. In contrast, dietary depletion of combined methyl donors predictably induces p53 hypomethylation within exons 6–7 of the p53 gene in rat liver (15,16). These observations suggest that p53 methylation changes likely depend on the degree of methyl donor supply and subsequent levels of methylation intermediates that are predictably and consistently achieved by combined methyl deficiency and not by isolated folate deficiency.
One critical factor that may explain the inability of folate deficiency to modulate genomic and site and gene-specific DNA methylation in the colorectum may be related to the fact that modulation of SAM and SAH in the colonic mucosa is particularly resistant to the level of dietary folate (32,36,41). The reason for this tenacious resistance to altered SAM and SAH levels in the colorectum compared with other tissues is unclear at present. A recent animal study using a moderate degree of dietary folate deficiency has suggested that the colon of old rats is more susceptible to changes in SAM and SAH in response to folate deficiency compared with that of young rats, although these changes in SAM and SAH do not appear to induce genomic DNA hypomethylation (42).
Effect of folate deficiency on DNA methylation in in vitro systems
In one study by Duthie et al. (43), normal human colonic epithelial cells were immortalized by SV40 T antigen and cultured in folate-deficient (<2.3 nmol/L) and control (9.1 µmol/L folic acid) medium for 14 d (43). Folate deficiency led to genomic DNA hypomethylation, increased uracil misincorporation, and inhibition of DNA excision repair in colonic epithelial cells. In contrast, a recent study, using 2 human colon adenocarcinoma cell lines, Caco2 and HCT116, has shown that the extent and the direction of the changes of SAM and SAH in response to folate deficiency (0.6 nmol/L folic acid in the medium vs. 2.3 µmol/L in control medium) are cell specific, and that genomic-, site- and gene-specific DNA methylation are not affected by the changes of SAM and SAH induced by folate depletion (44). In a similar experiment using nontransformed cell lines, folate deficiency (0.6 nmol/L in the medium) was shown to induce significant genomic DNA hypomethylation in both a mouse fibroblast cell line, NIH/3T3, and a Chinese hamster ovarian cell line, CHO-K1, by cell-specific mechanisms as indicated by cell-specific differential effects of folate deficiency on intracellular SAM, SAH, and DNMT (44). In another study, human nasopharyngeal carcinoma KB cells grown in folate-deplete (2–10 nmol/L folic acid) medium was associated with paradoxical hypermethylation in a 5' CpG island (by 40%) and consequent downregulation of the H-cadherin gene compared with cells grown in folate-replete (2.0 µmol/L folic acid) medium (45).
The results from these studies collectively suggest that the effects of folate deficiency on DNA methylation are site and gene specific. Also, the direction of methylation changes may be cell, target organ, and stage of transformation specific, and may not be the same between genomic and gene or site-specific DNA methylation. The major limitation of the in vitro system to study the effect of folate on DNA methylation is that the degree of folate deficiency and supplementation used in this system is not physiologically and clinically relevant and applicable to in vivo situations.
Effect of folate status on DNA methylation in humans
There are some observations in humans suggesting that altered folate status can affect genomic DNA methylation. Folate depletion in healthy human volunteers in a metabolic unit setting has been observed to diminish genomic DNA methylation in leukocytes (Table 2) (46,47). Rampersaud et al. (47) showed that lymphocyte genomic DNA methylation significantly decreased by 10% in response to moderate (118 µg folate/d) folate depletion for a period of 7 wk in elderly women (60–85 y of age). However, no significant changes in leukocyte genomic DNA methylation were detected during the 7-wk period of folate repletion with either 200 or 415 µg of folate/d (47). Another study by Jacob et al. (46) housed healthy, postmenopausal women (49–63 y of age) in a metabolic unit and fed them folate-deplete diets (56–111 µg folate/d) for 9 wk. This resulted in a significant (by 120%) degree of lymphocyte genomic DNA hypomethylation, which was reversed during the 3-wk period of folate supplementation (285–516 µg folate/d). However, an earlier study by the same group using healthy, younger males (33–46 y of age) failed to show a change in in vivo methylation capacity (as measured by the ability to methylate orally administered nicotinamide as detected in the urine as methylated metabolites) in response to dietary folate and methyl group restriction (25 µg folate/d for 30 d) (Table 2) (48).
|
In some human intervention studies, folate supplementation at 12.5–25 times the daily requirement for 3–12 mo significantly increased the extent of colonic genomic DNA methylation in subjects with resected colorectal adenoma or cancer (53–55), whereas no such effect was observed in patients with chronic ulcerative colitis who were given folate supplementation at 12.5 times the daily requirement for 6 mo (56) (Table 2). Folate supplementation at 5 times the daily requirement, which was sufficient to correct a marker of DNA damage, failed to modulate genomic DNA methylation in lymphocytes in healthy volunteers (49) (Table 2). In another study, folate supplementation with 15 mg methyltetrahydrofolate a day for 8 wk restored genomic DNA methylation in lymphocytes to normal levels in 32 men with uremia, hyperhomocysteinemia, and preexisting genomic DNA hypomethylation (Table 2) (57). A recent study has demonstrated that a physiological dose of folic acid (400 µg/d) for 10 wk increases genomic DNA methylation in lymphocytes (by 31%; P = 0.05) and in colonic mucosa (by 25%; P = 0.09) compared with placebo in patients with colorectal adenomas (Table 2) (58).
The data from these human studies collectively raise a possibility that the effect of folate status on genomic DNA methylation may be site and tissue specific, and may depend on the degree of folate depletion and supplementation. However, there is no conclusive data suggesting that folate deficiency, of a physiologically and clinical relevant degree, induces significant genomic DNA hypomethylation and/or site and gene-specific aberrant DNA methylation in the colorectum. In contrast, folate supplementation, even at modest levels, appears to be able to increase genomic DNA methylation in the colorectum in certain situations.
Conclusions
Genetic changes in cancer are abrupt in onset, their effects are often all-or-nothing, the loss of function occurs at a fixed level, and they are not reversible in most cases (14). In contrast, epigenetic changes are gradual in onset and progressive, their effects are dose-dependent, and are potentially reversible (14). These observations present new opportunities in cancer-risk modification and prevention using dietary and lifestyle factors and potential chemopreventive drugs. In this regard, folate has been a focus of intense interest because of an inverse association between folate status and the risk of several malignancies and of its potential ability to modulate DNA methylation (15). The portfolio of evidence from animal and in vitro studies collectively suggests that the effects of folate deficiency on DNA methylation are highly complex and appear to depend on cell type, target organ, and stage of transformation, and are gene and site specific. These studies also suggest that changes in DNA methylation induced by folate deficiency may be mediated via both SAM and SAH dependent and independent pathways. Also, there is evidence suggesting that the pattern of site- and gene-specific DNA methylation may not be in concert with the direction of changes in genomic DNA methylation. Currently available data pertaining to the effects of folate deficiency on DNA methylation in the liver and colon in animal studies are inconsistent and do not support the hypothesis that folate deficiency induces DNA hypomethylation in the colon. Although some similarities do exist, these animal models differ in several important physiological aspects from humans, including bioavailability, metabolism, and excretion of folate (17). Therefore, any extrapolation of the observations from these models to human situations should be made very cautiously. Furthermore, these animal models may produce variable results owing to species differences, different diet compositions, and variable dose, time, and duration of folate manipulations.
In contrast, human feeding studies in metabolic unit settings have shown a consistent, significant hypomethylating effect of folate deficiency in genomic lymphocytes DNA (46,47). However, the effect of physiologically and clinically relevant folate deficiency on DNA methylation in the colorectum has not been studied in humans. Folate supplementation appears to be capable of increasing the degree of DNA methylation in the colorectum in some human studies (53–55,58). Although the jury is still out, the potential for folate to modulate DNA methylation and thus modify colorectal cancer risk remains biologically plausible and is worthy of further studies.
FOOTNOTES
1 Presented as part of the symposium "Nutritional ‘Omics’ Technologies for Elucidating the Roles of Bioactive Food Components in Colon Cancer Prevention" given at the 2005 Experimental Biology meeting on April 5, 2005, San Diego, CA. The symposium was sponsored by the American Society for Nutritional Sciences and in part by the Diet and Cancer and Dietary Bioactive Food Components Research Interest Sections. The proceedings are published as a supplement to The Journal of Nutrition. This supplement is the responsibility of the Guest Editors to whom the Editor of The Journal of Nutrition has delegated supervision of both technical conformity to the published regulations of The Journal of Nutrition and general oversight of the scientific merit of each article. The opinions expressed in this publication are those of the authors and are not attributable to the sponsors or the publisher, editor, or editorial board of The Journal of Nutrition. The guest editors for the supplement publication are Cindy D. Davis, National Cancer Institute, National Institutes of Health, and Norman Hord, Department of Food Science and Human Nutrition, Michigan State University. 
2 This project has been supported by grants from the Canadian Institutes of Health Research.
4 Abbreviations used: AOM, azoxymethane; CDK, cyclin-dependent kinase; CpG, cytosine-guanine; DMH, dimethylhydrazine; DNMT, DNA methyltransferase; SAH, S-adenosyl-homocysteine; SAM, S-adenosylmethionine.
LITERATURE CITED
1. Esteller M. Relevance of DNA methylation in the management of cancer. Lancet Oncol. 2003;4:351-358.[Medline]
2. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004;429:457-463.[Medline]
3. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3:415-428.[Medline]
4. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349:2042-2054.
5. Robertson KD, Wolffe AP. DNA methylation in health and disease. Nat Rev Genet. 2000;1:11-19.[Medline]
6. Takai D, Jones PA. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci U S A. 2002;99:3740-3745.
7. Li E, Jaenisch R. DNA methylation and methyltransferases. Ehrlich M eds. DNA methylation and methyltransferases. DNA alterations in cancer: genetic and epigenetic changes. :351-365 Eaton Publishing Natick (MA):.
8. Laird PW, Jackson-Grusby L, Fazeli A, Dickinson SL, Jung WE, Li E, Weinberg RA, Jaenisch R. Suppression of intestinal neoplasia by DNA hypomethylation. Cell. 1995;81:197-205.[Medline]
9. Trinh BN, Long TI, Nickel AE, Shibata D, Laird PW. DNA methyltransferase deficiency modifies cancer susceptibility in mice lacking DNA mismatch repair. Mol Cell Biol. 2002;22:2906-2917.
10. Gaudet F, Hodgson JG, Eden A, Jackson-Grusby L, Dausman J, Gray JW, Leonhardt H, Jaenisch R. Induction of tumors in mice by genomic hypomethylation. Science. 2003;300:489-492.
11. Eden A, Gaudet F, Waghmare A, Jaenisch R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science. 2003;300:455.
12. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res. 2001;61:3225-3229.
13. Zingg JM, Jones PA. Genetic and epigenetic aspects of DNA methylation on genome expression, evolution, mutation and carcinogenesis. Carcinogenesis. 1997;18:869-882.
14. Ballestar E, Esteller M. The impact of chromatin in human cancer: linking DNA methylation to gene silencing. Carcinogenesis. 2002;23:1103-1109.
15. Kim YI. Folate and DNA methylation: a mechanistic link between folate deficiency and colorectal cancer?. Cancer Epidemiol Biomarkers Prev. 2004;13:511-519.
16. Kim YI. Folate and carcinogenesis: evidence, mechanisms, and implications. J Nutr Biochem. 1999;10:66-88.[Medline]
17. Kim YI. Role of folate in colon cancer development and progression. J Nutr. 2003;133:3731S-3739S.
18. Giovannucci E. Epidemiologic studies of folate and colorectal neoplasia: a review. J Nutr. 2002;132:2350S-2355S.
19. Giovannucci E, Rimm EB, Ascherio A, Stampfer MJ, Colditz GA, Willett WC. Alcohol, low-methionine–low-folate diets, and risk of colon cancer in men. J Natl Cancer Inst. 1995;87:265-273.
20. Giovannucci E, Stampfer MJ, Colditz GA, Hunter DJ, Fuchs C, Rosner BA, Speizer FE, Willett WC. Multivitamin use, folate, and colon cancer in women in the Nurses’ Health Study. Ann Intern Med. 1998;129:517-524.
21. Jacobs EJ, Connell CJ, Patel AV, Chao A, Rodriguez C, Seymour J, McCullough ML, Calle EE, Thun MJ. Multivitamin use and colon cancer mortality in the Cancer Prevention Study II cohort (United States). Cancer Causes Control. 2001;12:927-934.[Medline]
22. Kim YI. Will mandatory folic acid fortification prevent or promote cancer?. Am J Clin Nutr. 2004;80:1123-1128.
23. Selhub J, Miller JW. The pathogenesis of homocysteinemia: interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine. Am J Clin Nutr. 1992;55:131-138.
24. Cravo ML, Mason JB, Dayal Y, Hutchinson M, Smith D, Selhub J, Rosenberg IH. Folate deficiency enhances the development of colonic neoplasia in dimethylhydrazine-treated rats. Cancer Res. 1992;52:5002-5006.
25. Duthie SJ, Narayanan S, Brand GM, Grant G. DNA stability and genomic methylation status in colonocytes isolated from methyl-donor-deficient rats. Eur J Nutr. 2000;39:106-111.[Medline]
26. Wolff GL, Kodell RL, Moore SR, Cooney CA. Maternal epigenetics and methyl supplements affect agouti gene expression in Avy/a mice. FASEB J. 1998;12:949-957.
27. Cooney CA, Dave AA, Wolff GL. Maternal methyl supplements in mice affect epigenetic variation and DNA methylation of offspring. J Nutr. 2002;132:2393S-2400S.
28. Waterland RA, Jirtle RL. Transposable elements: targets for early nutritional effects on epigenetic gene regulation. Mol Cell Biol. 2003;23:5293-5300.
29. Kim YI, Miller JW, da Costa KA, Nadeau M, Smith D, Selhub J, Zeisel S.H, Mason JB. Severe folate deficiency causes secondary depletion of choline and phosphocholine in rat liver. J Nutr. 1994;124:2197-2203.
30. Miller JW, Nadeau MR, Smith J, Smith D, Selhub J. Folate-deficiency-induced homocysteinaemia in rats: disruption of S-adenosylmethionine’s co-ordinate regulation of homocysteine metabolism. Biochem J. 1994;298(Pt 2):415-419.
31. Balaghi M, Horne DW, Wagner C. Hepatic one-carbon metabolism in early folate deficiency in rats. Biochem J. 1993;291(Pt 1):145-149.
32. Kim YI, Christman JK, Fleet JC, Cravo ML, Salomon RN, Smith D, Ordovas J, Selhub J, Mason JB. Moderate folate deficiency does not cause global hypomethylation of hepatic and colonic DNA or c-myc-specific hypomethylation of colonic DNA in rats. Am J Clin Nutr. 1995;61:1083-1090.
33. Kim YI, Pogribny IP, Basnakian AG, Miller JW, Selhub J, James SJ, Mason JB. Folate deficiency in rats induces DNA strand breaks and hypomethylation within the p53 tumor suppressor gene. Am J Clin Nutr. 1997;65:46-52.
34. Balaghi M, Wagner C. DNA methylation in folate deficiency: use of CpG methylase. Biochem Biophys Res Commun. 1993;193:1184-1190.[Medline]
35. Song J, Sohn KJ, Medline A, Ash C, Gallinger S, Kim YI. Chemopreventive effects of dietary folate on intestinal polyps in Apc+/-Msh2-/- mice. Cancer Res. 2000;60:3191-3199.
36. Kim YI, Salomon RN, Graeme-Cook F, Choi SW, Smith DE, Dallal GE, Mason JB. Dietary folate protects against the development of macroscopic colonic neoplasia in a dose responsive manner in rats. Gut. 1996;39:732-740.
37. Le Leu RK, Young GP, McIntosh GH. Folate deficiency diminishes the occurrence of aberrant crypt foci in the rat colon but does not alter global DNA methylation status. J Gastroenterol Hepatol. 2000;15:1158-1164.[Medline]
38. Le Leu RK, Young GP, McIntosh GH. Folate deficiency reduces the development of colorectal cancer in rats. Carcinogenesis. 2000;21:2261-2265.
39. Davis CD, Uthus EO. Dietary folate and selenium affect dimethylhydrazine-induced aberrant crypt formation, global DNA methylation and one-carbon metabolism in rats. J Nutr. 2003;133:2907-2914.
40. Kim YI, Pogribny IP, Salomon RN, Choi SW, Smith DE, James SJ, Mason JB. Exon-specific DNA hypomethylation of the p53 gene of rat colon induced by dimethylhydrazine. Modulation by dietary folate. Am J Pathol. 1996;149:1129-1137.[Abstract]
41. Sohn KJ, Stempak JM, Reid S, Shirwadkar S, Mason JB, Kim YI. The effect of dietary folate on genomic and p53-specific DNA methylation in rat colon. Carcinogenesis. 2003;24:81-90.
42. Choi SW, Friso S, Dolnikowski GG, Bagley PJ, Edmondson AN, Smith DE, Mason JB. Biochemical and molecular aberrations in the rat colon due to folate depletion are age-specific. J Nutr. 2003;133:1206-1212.
43. Duthie SJ, Narayanan S, Blum S, Pirie L, Brand GM. Folate deficiency in vitro induces uracil misincorporation and DNA hypomethylation and inhibits DNA excision repair in immortalized normal human colon epithelial cells. Nutr Cancer. 2000;37:245-251.[Medline]
44. Stempak JM, Sohn KJ, Chiang EP, Shane B, Kim YI. Cell and stage of transformation-specific effects of folate deficiency on methionine cycle intermediates and DNA methylation in an in vitro model. Carcinogenesis. 2005;26:981-990.
45. Jhaveri MS, Wagner C, Trepel JB. Impact of extracellular folate levels on global gene expression. Mol Pharmacol. 2001;60:1288-1295.
46. Jacob RA, Gretz DM, Taylor PC, James SJ, Pogribny IP, Miller BJ, Henning SM, Swendseid ME. Moderate folate depletion increases plasma homocysteine and decreases lymphocyte DNA methylation in postmenopausal women. J Nutr. 1998;128:1204-1212.
47. Rampersaud GC, Kauwell GP, Hutson AD, Cerda JJ, Bailey LB. Genomic DNA methylation decreases in response to moderate folate depletion in elderly women. Am J Clin Nutr. 2000;72:998-1003.
48. Jacob RA, Pianalto FS, Henning SM, Zhang JZ, Swendseid ME. In vivo methylation capacity is not impaired in healthy men during short-term dietary folate and methyl group restriction. J Nutr. 1995;125:1495-1502.
49. Fenech M, Aitken C, Rinaldi J. Folate, vitamin B12, homocysteine status and DNA damage in young Australian adults. Carcinogenesis. 1998;19:1163-1171.
50. Pufulete M, Al-Ghnaniem R, Leather AJ, Appleby P, Gout S, Terry C, Emery PW, Sanders TA. Folate status, genomic DNA hypomethylation, and risk of colorectal adenoma and cancer: a case control study. Gastroenterology. 2003;124:1240-1248.[Medline]
51. Pufulete M, Al-Ghnaniem R, Rennie JA, Appleby P, Harris N, Gout S, Emery PW, Sanders TA. Influence of folate status on genomic DNA methylation in colonic mucosa of subjects without colorectal adenoma or cancer. Br J Cancer. 2005;92:838-842.[Medline]
52. van Engeland M, Weijenberg MP, Roemen GM, Brink M, de Bruine AP, Goldbohm RA, van den Brandt PA, Baylin SB, de Goeij AF, Herman JG. Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: the Netherlands cohort study on diet and cancer. Cancer Res. 2003;63:3133-3137.
53. Cravo M, Fidalgo P, Pereira AD, Gouveia-Oliveira A, Chaves P, Selhub J, Mason JB, Mira FC, Leitao CN. DNA methylation as an intermediate biomarker in colorectal cancer: modulation by folic acid supplementation. Eur J Cancer Prev. 1994;3:473-479.[Medline]
54. Cravo ML, Pinto AG, Chaves P, Cruz JA, Lage P, Nobre Leitao C, Costa Mira F. Effect of folate supplementation on DNA methylation of rectal mucosa in patients with colonic adenomas: correlation with nutrient intake. Clin Nutr. 1998;17:45-49.[Medline]
55. Kim YI, Baik HW, Fawaz K, Knox T, Lee YM, Norton R, Libby E, Mason JB. Effects of folate supplementation on two provisional molecular markers of colon cancer: a prospective, randomized trial. Am J Gastroenterol. 2001;96:184-195.[Medline]
56. Cravo M, Gloria L, Salazar De Sousa L, Chaves P, Dias Pereira A, Quina M, Nobre Leitao C, Costa Mira F. Folate status, DNA methylation, and colon cancer risk in inflammatory bowel disease. Clin Nutr. 1995;14:50-53.
57. Ingrosso D, Cimmino A, Perna AF, Masella L, De Santo NG, De Bonis ML, Vacca M, D’Esposito M, D’Urso M, et al. Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinaemia in patients with uraemia. Lancet. 2003;361:1693-1699.[Medline]
58. Pufulete M, Al-Ghnaniem R, Khushal A, Appleby P, Harris N, Gout S, Emery PW, Sanders TA. Effect of folic acid supplementation on genomic DNA methylation in patients with colorectal adenoma. Gut. 2005;54:648-653.
This article has been cited by other articles:
|
|
 |
|
  J. Kotsopoulos, K.-J. Sohn, and Y.-I. Kim Postweaning Dietary Folate Deficiency Provided through Childhood to Puberty Permanently Increases Genomic DNA Methylation in Adult Rat Liver J. Nutr., April 1, 2008; 138(4): 703 - 709. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A D. Smith, Y.-I. Kim, and H. Refsum Is folic acid good for everyone? Am. J. Clinical Nutrition, March 1, 2008; 87(3): 517 - 533. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Sadikovic, J. Andrews, D. Carter, J. Robinson, and D. I. Rodenhiser Genome-wide H3K9 Histone Acetylation Profiles Are Altered in Benzopyrene-treated MCF7 Breast Cancer Cells J. Biol. Chem., February 15, 2008; 283(7): 4051 - 4060. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Y. Jung, E. M. Poole, J. Bigler, J. Whitton, J. D. Potter, and C. M. Ulrich DNA Methyltransferase and Alcohol Dehydrogenase: Gene-Nutrient Interactions in Relation to Risk of Colorectal Polyps Cancer Epidemiol. Biomarkers Prev., February 1, 2008; 17(2): 330 - 338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Ericson, E. Sonestedt, B. Gullberg, H. Olsson, and E. Wirfalt High folate intake is associated with lower breast cancer incidence in postmenopausal women in the Malmo Diet and Cancer cohort Am. J. Clinical Nutrition, August 1, 2007; 86(2): 434 - 443. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Curtin, M. L. Slattery, C. M. Ulrich, J. Bigler, T. R. Levin, R. K. Wolff, H. Albertsen, J. D. Potter, and W. S. Samowitz Genetic polymorphisms in one-carbon metabolism: associations with CpG island methylator phenotype (CIMP) in colon cancer and the modifying effects of diet Carcinogenesis, August 1, 2007; 28(8): 1672 - 1679. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Hazra, K. Wu, P. Kraft, C. S. Fuchs, E. L. Giovannucci, and D. J. Hunter Twenty-four non-synonymous polymorphisms in the one-carbon metabolic pathway and risk of colorectal adenoma in the Nurses' Health Study Carcinogenesis, July 1, 2007; 28(7): 1510 - 1519. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Hayashi, K.-J. Sohn, J. M. Stempak, R. Croxford, and Y.-I. Kim Folate Deficiency Induces Cell-Specific Changes in the Steady-State Transcript Levels of Genes Involved in Folate Metabolism and 1-Carbon Transfer Reactions in Human Colonic Epithelial Cells J. Nutr., March 1, 2007; 137(3): 607 - 613. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Riedijk, B. Stoll, S. Chacko, H. Schierbeek, A. L. Sunehag, J. B. van Goudoever, and D. G. Burrin Methionine transmethylation and transsulfuration in the piglet gastrointestinal tract PNAS, February 27, 2007; 104(9): 3408 - 3413. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Tammali, K. V. Ramana, S. S. Singhal, S. Awasthi, and S. K. Srivastava Aldose Reductase Regulates Growth Factor-Induced Cyclooxygenase-2 Expression and Prostaglandin E2 Production in Human Colon Cancer Cells Cancer Res., October 1, 2006; 66(19): 9705 - 9713. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y-I Kim Folate: a magic bullet or a double edged sword for colorectal cancer prevention? Gut, October 1, 2006; 55(10): 1387 - 1389. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
